-
1
-
-
0033554684
-
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group
-
1:STN:280:DyaK1MvjsFGnsg%3D%3D 10519894 10.1056/NEJM199910143411601
-
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
-
(1999)
N Engl J Med
, vol.341
, pp. 1165-1173
-
-
Matthay, K.K.1
Villablanca, J.G.2
Seeger, R.C.3
Stram, D.O.4
Harris, R.E.5
Ramsay, N.K.6
-
2
-
-
40749114771
-
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial
-
1:CAS:528:DC%2BD1cXivVaqtb8%3D 18308250 10.1016/S1470-2045(08)70069-X
-
Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008;9:247-56.
-
(2008)
Lancet Oncol
, vol.9
, pp. 247-256
-
-
Pearson, A.D.1
Pinkerton, C.R.2
Lewis, I.J.3
Imeson, J.4
Ellershaw, C.5
Machin, D.6
-
3
-
-
56749151178
-
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group
-
18704922 10.1002/pbc.21713
-
Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:747-53.
-
(2008)
Pediatr Blood Cancer
, vol.51
, pp. 747-753
-
-
Zage, P.E.1
Kletzel, M.2
Murray, K.3
Marcus, R.4
Castleberry, R.5
Zhang, Y.6
-
4
-
-
80051979836
-
Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group project
-
3158599 21768459 10.1200/JCO.2010.34.3392
-
London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011;29:3286-92.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3286-3292
-
-
London, W.B.1
Castel, V.2
Monclair, T.3
Ambros, P.F.4
Pearson, A.D.5
Cohn, S.L.6
-
5
-
-
77954522656
-
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: Results of a meta-analysis
-
1:CAS:528:DC%2BC3cXnvVaksr8%3D 20392867 10.1210/jc.2009-2604
-
Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR.123I-meta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010;95:2596-606.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 2596-2606
-
-
Jacobson, A.F.1
Deng, H.2
Lombard, J.3
Lessig, H.J.4
Black, R.R.5
-
6
-
-
77951675606
-
Development of a semi-quantitative I-123 mIBG reporting method in high risk neuroblastoma
-
Lewington V, Bar Sever Z, Giammarile F, Lynch T, McEwan A, Shulkin B, et al. Development of a semi-quantitative I-123 mIBG reporting method in high risk neuroblastoma. J Nucl Med 2009;50:1379.
-
(2009)
J Nucl Med
, vol.50
, pp. 1379
-
-
Lewington, V.1
Bar Sever, Z.2
Giammarile, F.3
Lynch, T.4
McEwan, A.5
Shulkin, B.6
-
7
-
-
0038013985
-
Correlation of early metastatic response by123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
-
12829667 10.1200/JCO.2003.09.122
-
Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, et al. Correlation of early metastatic response by123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-91.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2486-2491
-
-
Matthay, K.K.1
Edeline, V.2
Lumbroso, J.3
Tanguy, M.L.4
Asselain, B.5
Zucker, J.M.6
-
8
-
-
79954603164
-
18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: Diagnostic comparison and survival analysis
-
1:CAS:528:DC%2BC3MXlslKqsb8%3D 21421719 10.2967/jnumed.110.083303
-
Papathanasiou ND, Gaze MN, Sullivan K, Aldridge M, Waddington W, Almuhaideb A, et al. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med 2011;52:519-25.
-
(2011)
J Nucl Med
, vol.52
, pp. 519-525
-
-
Papathanasiou, N.D.1
Gaze, M.N.2
Sullivan, K.3
Aldridge, M.4
Waddington, W.5
Almuhaideb, A.6
-
9
-
-
33750483287
-
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
-
16444675 10.1002/pbc.20777
-
Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865-74.
-
(2006)
Pediatr Blood Cancer
, vol.47
, pp. 865-874
-
-
Messina, J.A.1
Cheng, S.C.2
Franc, B.L.3
Charron, M.4
Shulkin, B.5
To, B.6
-
10
-
-
84858776675
-
Comparison of (18)F-dopa PET/CT and (123)I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: A pilot study
-
1:CAS:528:DC%2BC3MXhsFOgt7bM 21932116 10.1007/s00259-011-1938-2
-
Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of (18)F-dopa PET/CT and (123)I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012;39:57-61.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 57-61
-
-
Piccardo, A.1
Lopci, E.2
Conte, M.3
Garaventa, A.4
Foppiani, L.5
Altrinetti, V.6
-
11
-
-
84858147946
-
18F-DOPA PET/CT in neuroblastoma: Comparison of conventional imaging with CT/MR
-
22391727 10.1097/RLU.0b013e3182485172
-
Lopci E, Piccardo A, Nanni C, Altrinetti V, Garaventa A, Pession A, et al. 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med 2012;37:e73-8.
-
(2012)
Clin Nucl Med
, vol.37
-
-
Lopci, E.1
Piccardo, A.2
Nanni, C.3
Altrinetti, V.4
Garaventa, A.5
Pession, A.6
-
12
-
-
84872046559
-
Characterization of neuroblastic tumors using 18F-FDOPA PET
-
1:CAS:528:DC%2BC3sXhvFGjt7g%3D 23213196 10.2967/jnumed.112.102772
-
Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH, et al. Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med 2013;54:42-9.
-
(2013)
J Nucl Med
, vol.54
, pp. 42-49
-
-
Lu, M.Y.1
Liu, Y.L.2
Chang, H.H.3
Jou, S.T.4
Yang, Y.L.5
Lin, K.H.6
-
13
-
-
62349083799
-
Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP publication 53 ICRP publication 106
-
ICRP
-
ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP publication 53. ICRP publication 106. Ann ICRP 2008;38(1-2):1-197.
-
(2008)
Ann ICRP
, vol.38
, Issue.1-2
, pp. 1-197
-
-
-
14
-
-
0032293521
-
Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53)
-
ICRP ICRP Publication 80
-
ICRP. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). ICRP Publication 80. Ann ICRP 1998;28(3):1-126.
-
(1998)
Ann ICRP
, vol.28
, Issue.3
, pp. 1-126
-
-
-
15
-
-
0027239723
-
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
-
1:STN:280:DyaK3szivFCrug%3D%3D 8336186
-
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1466-1477
-
-
Brodeur, G.M.1
Pritchard, J.2
Berthold, F.3
Carlsen, N.L.4
Castel, V.5
Castelberry, R.P.6
-
16
-
-
34247617336
-
The new EANM paediatric dosage card
-
EANM Dosimetry and Paediatrics Committees 1:STN:280: DC%2BD2s3kvFKgsg%3D%3D 17406866 10.1007/s00259-007-0370-0
-
Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F, EANM Dosimetry and Paediatrics Committees. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 2007;34:796-8.
-
(2007)
Eur J Nucl Med Mol Imaging
, vol.34
, pp. 796-798
-
-
Lassmann, M.1
Biassoni, L.2
Monsieurs, M.3
Franzius, C.4
Jacobs, F.5
-
17
-
-
77951688395
-
Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force
-
1:STN:280:DC%2BC3c3psVSrsA%3D%3D 2865749 20424613 10.1038/sj.bjc.6605621
-
Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Levington V, et al. Criteria for evaluation of disease extent by 123I- metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102:1319-22.
-
(2010)
Br J Cancer
, vol.102
, pp. 1319-1322
-
-
Matthay, K.K.1
Shulkin, B.2
Ladenstein, R.3
Michon, J.4
Giammarile, F.5
Levington, V.6
-
18
-
-
12444301364
-
Guidelines for radioiodinated MIBG scintigraphy in children
-
12658506 10.1007/s00259-003-1138-9
-
Olivier P, Colarinha P, Fettich J, Fischer S, Frökier J, Giammarile F, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003;30:B45-50.
-
(2003)
Eur J Nucl Med Mol Imaging
, vol.30
-
-
Olivier, P.1
Colarinha, P.2
Fettich, J.3
Fischer, S.4
Frökier, J.5
Giammarile, F.6
-
19
-
-
0025276053
-
Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET
-
1:CAS:528:DyaK3cXltlaksbw%3D 2158953 10.1016/0883-2889(90)90191-I
-
Luxen A, Perlmutter M, Bida GT, Van Moffaert G, Cook JS, Satyamurthy N, et al. Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum A 1990;41:275-81.
-
(1990)
Int J Rad Appl Instrum A
, vol.41
, pp. 275-281
-
-
Luxen, A.1
Perlmutter, M.2
Bida, G.T.3
Van Moffaert, G.4
Cook, J.S.5
Satyamurthy, N.6
-
20
-
-
70349904742
-
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess
-
1:CAS:528:DC%2BD1MXht12ru7bM 19622618 10.1210/jc.2009-1054
-
Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009;94:3922-30.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 3922-3930
-
-
Fiebrich, H.B.1
Brouwers, A.H.2
Kerstens, M.N.3
Pijl, M.E.4
Kema, I.P.5
De Jong, J.R.6
-
21
-
-
43149124822
-
Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: A novel approach with fluorodeoxyglucose-PET
-
1:CAS:528:DC%2BD1cXlsV2gtbY%3D 18458598 10.1097/MNM.0b013e3282f813a4
-
Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 2008;29:521-6.
-
(2008)
Nucl Med Commun
, vol.29
, pp. 521-526
-
-
Berkowitz, A.1
Basu, S.2
Srinivas, S.3
Sankaran, S.4
Schuster, S.5
Alavi, A.6
-
22
-
-
0036301604
-
Utility of follow-up studies using meta-[123 I]iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma
-
1:STN:280:DC%2BD38zks1Giug%3D%3D 12089489 10.1097/00006231-200207000- 00011
-
Okuyama C, Ushijima Y, Kubota T, Nakamura T, Kikkawa M, Nishimura T. Utility of follow-up studies using meta-[123 I]iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl Med Commun 2002;23:663-72.
-
(2002)
Nucl Med Commun
, vol.23
, pp. 663-672
-
-
Okuyama, C.1
Ushijima, Y.2
Kubota, T.3
Nakamura, T.4
Kikkawa, M.5
Nishimura, T.6
-
23
-
-
61449184564
-
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma
-
2667809 19171710 10.1200/JCO.2008.17.6107
-
Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009;27:1041-6.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1041-1046
-
-
Kushner, B.H.1
Kramer, K.2
Modak, S.3
Cheung, N.K.4
-
24
-
-
33644847831
-
Neuroblastoma in adolescents: The Italian experience
-
1:CAS:528:DC%2BD28XjtVCrtr8%3D 16475209 10.1002/cncr.21751
-
Conte M, Parodi S, De Bernardi B, Milanaccio C, Mazzocco K, Angelini P, et al. Neuroblastoma in adolescents: the Italian experience. Cancer 2006;106:1409-17.
-
(2006)
Cancer
, vol.106
, pp. 1409-1417
-
-
Conte, M.1
Parodi, S.2
De Bernardi, B.3
Milanaccio, C.4
Mazzocco, K.5
Angelini, P.6
-
25
-
-
84880313396
-
Current and future strategies for relapsed neuroblastoma: Challenges on the road to precision therapy
-
1:CAS:528:DC%2BC3sXhtVShs7zN 23703550 10.1097/MPH.0b013e318299d637
-
Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol 2013;35:337-47.
-
(2013)
J Pediatr Hematol Oncol
, vol.35
, pp. 337-347
-
-
Morgenstern, D.A.1
Baruchel, S.2
Irwin, M.S.3
|